Some Observations on the Use of Bretylium Tosylate in Pregnancy

Abstract

Summary The use of bretylium tosylate in hypertensive pregnant women is discussed. Using C‐14 labelled material there is evidence of placental transfer but this does not appear to affect the foetus adversely. In 12 patients, Darenthin adequately controlled the blood pressure of both essential hypertension complicating pregnancy and pre‐eclampsia. There is insufficient evidence to show whether or not this control improves foetal prognosis or modifies other manifestations of toxaemia. In 1 patient, therapy was discontinued because of severe urticaria.

Potentially Harmful Effects of Drugs on the Foetus:A report prepared for the Australian Regional Council of the Royal College of Obstetricians and Gynaecologists*

“…(b) Post-ganglionic drugs: Studies with C1'-labelled bretylium iodide have shown that this preparation crosses the placenta and can be found in liquor and in foetal blood of both animals and human (Whiley et al, 1961). There is no evidence that this has any significance with regard to foetal welfare.…”